{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T17:26:01Z","timestamp":1787073961639,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008018","name":"Victorian Cancer Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clinthera.2026.06.018","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T19:56:21Z","timestamp":1784577381000},"page":"841-846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase I\/II Double-Blind, Randomized Controlled Trial of Medicinal Cannabis on Quality of Life and Symptoms in Advanced Cancer: RESONANCE Trial Protocol"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6507-1219","authenticated-orcid":false,"given":"Aaron K.","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"Grobler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlene","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Galettis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Philip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Cebon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.06.018_bib0001","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/FTD.0000000000000698","article-title":"Using therapeutic drug monitoring and pharmacovigilance to overcome some of the challenges of developing medicinal cannabis from botanical origins","volume":"42","author":"Dryburgh","year":"2020","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0002","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.mayocp.2011.10.003","article-title":"Blurred boundaries: the therapeutics and politics of medical marijuana","volume":"87","author":"Bostwick","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0003","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/pds.1152","article-title":"Limited use of medicinal cannabis but for labeled indications after legalization","volume":"14","author":"Erkens","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0004","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: a systematic review and meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0005","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S2215-0366(26)00015-5","article-title":"The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis","volume":"13","author":"Wilson","year":"2026","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0006","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1111\/bcp.13657","article-title":"Medical cannabis: aligning use to evidence-based medicine approach","volume":"84","author":"Bar-Lev Schleider","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0007","doi-asserted-by":"crossref","first-page":"211","DOI":"10.5694\/mja17.01247","article-title":"Medicinal cannabis in Australia, 2016: the Cannabis as Medicine Survey (CAMS-16)","volume":"209","author":"Lintzeris","year":"2018","journal-title":"Med J Aust"},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2026.06.018_bib0008","first-page":"28","article-title":"Results of a standardized survey on the medical use of cannabis products in the German-speaking area [in German]","volume":"6","author":"Schnelle","year":"1999","journal-title":"Forsch Komplementarmed"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0009","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12954-024-00992-1","article-title":"Medical cannabis use in Australia seven years after legalisation: findings from the online Cannabis as Medicine Survey 2022-2023 (CAMS-22)","volume":"21","author":"Mills","year":"2024","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0010","series-title":"Cancer Fact Sheets - All Cancers","year":"2023"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0011","doi-asserted-by":"crossref","first-page":"e2128","DOI":"10.1136\/spcare-2024-005028","article-title":"Opioid initiation timing and palliative care referrals in advanced cancer: retrospective study","volume":"14","author":"Wong","year":"2024","journal-title":"BMJ Support Palliat Care"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0012","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1017\/S147895151000057X","article-title":"A review of the literature on multiple symptoms, their predictors, and associated outcomes in patients with advanced cancer","volume":"9","author":"Gilbertson-White","year":"2011","journal-title":"Palliat Support Care"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0013","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4103\/0973-1075.179601","article-title":"A prospective evaluation of symptom prevalence and overall symptom burden among cohort of critically ill cancer patients","volume":"22","author":"Gupta","year":"2016","journal-title":"Indian J Palliat Care"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0014","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jpainsymman.2010.10.266","article-title":"Symptom clusters in advanced cancer","volume":"42","author":"Jim\u00e9nez","year":"2011","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0015","doi-asserted-by":"crossref","first-page":"e335","DOI":"10.1016\/j.jpainsymman.2023.05.020","article-title":"Prevalence, severity, and predictors of insomnia in advanced colorectal cancer","volume":"66","author":"Wong","year":"2023","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0016","first-page":"436","article-title":"Defining research priorities and needs in cancer symptoms for adults diagnosed with cancer: an Australian\/New Zealand modified Delphi study","volume":"31","author":"Yenson","year":"2023","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0017","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s42238-020-00038-w","article-title":"Medical cannabis use in the United States: a retrospective database study","volume":"2","author":"Mahabir","year":"2020","journal-title":"J Cannabis Res"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0018","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.12522","article-title":"Assessment of medical cannabis and health-related quality of life","volume":"6","author":"Arkell","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0019","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_431554","article-title":"Integrative Therapies in cancer care: an update on the guidelines","volume":"44","author":"Gowin","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0020","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0021","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singap"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0022","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1023\/A:1016670403148","article-title":"Re-validation and shortening of the Functional Assessment of Anorexia\/Cachexia Therapy (FAACT) questionnaire","volume":"9","author":"Ribaudo","year":"2000","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0023","doi-asserted-by":"crossref","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0024","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1389-9457(00)00065-4","article-title":"Validation of the Insomnia Severity Index as an outcome measure for insomnia research","volume":"2","author":"Bastien","year":"2001","journal-title":"Sleep Med"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0025","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0026","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1023\/A:1026407010614","article-title":"The Caregiver Quality of Life Index-Cancer (CQOLC) scale: development and validation of an instrument to measure quality of life of the family caregiver of patients with cancer","volume":"8","author":"Weitzner","year":"1999","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0027","unstructured":"U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/forsites\/adverse-events. Accessed Jan 9, 2026."},{"key":"10.1016\/j.clinthera.2026.06.018_bib0028","doi-asserted-by":"crossref","first-page":"6380","DOI":"10.2174\/1381612822666160826105628","article-title":"Cannabinoids and psychosis","volume":"22","author":"D'Souza","year":"2016","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0029","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1186\/s13063-024-08091-z","article-title":"Medicinal cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC\/CBD (1:20) to relieve symptom burden in patients with cancer\u2014a study protocol for a randomised controlled trial","volume":"25","author":"Gurgenci","year":"2024","journal-title":"Trials"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.conctc.2022.101036","article-title":"ENhANCE trial protocol: a multi-centre, randomised, phase IV trial comparing the efficacy of oxycodone\/naloxone prolonged release (OXN PR) versus oxycodone prolonged release (Oxy PR) tablets in patients with advanced cancer","volume":"30","author":"Wong","year":"2022","journal-title":"Contemp Clin Trials Commun"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0031","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1177\/02692163251362563","article-title":"Oxycodone\/naloxone PR versus oxycodone PR in advanced cancer: a multi-centre randomised trial (ENhANCE trial)","volume":"39","author":"Wong","year":"2025","journal-title":"Palliat Med"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0033","series-title":"Cannabinoids - Recent Perspectives and Applications in Human Health","article-title":"Cannabis medicines: guidance for the selection, purchase and supply for clinical trials","author":"Weston-Green","year":"2022"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-030-57369-0_1","article-title":"Constituents of cannabis sativa","volume":"1264","author":"Rock","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0035","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1111\/bcp.13710","article-title":"The pharmacokinetics and the pharmacodynamics of cannabinoids","volume":"84","author":"Lucas","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0036","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1089\/can.2023.0229","article-title":"Comparative pharmacokinetic assessment of innovative sublingual, rectal and vaporizer cannabis products versus approved cannabis products in healthy volunteers","volume":"10","author":"Tarlovski","year":"2025","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.clinthera.2026.06.018_bib0037","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s42238-025-00294-8","article-title":"Enhancing cannabinoid bioavailability: a crossover study comparing a novel self-nanoemulsifying drug delivery system and a commercial oil-based formulation","volume":"7","author":"Hermush","year":"2025","journal-title":"J Cannabis Res"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182600233X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182600233X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:34:29Z","timestamp":1787070869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929182600233X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S014929182600233X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.06.018","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I\/II Double-Blind, Randomized Controlled Trial of Medicinal Cannabis on Quality of Life and Symptoms in Advanced Cancer: RESONANCE Trial Protocol","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}